Not Tagged
zymeworks
[]
$zyme +5% ph 2 data at asco-gi survival at 18 mo in her2-expressing metastatic gastroesophageal adenocarcinoma overall confirmed objective response rate of 79%, disease control rate of 92%, and median progression-free survival of 12.5 months 
Catalyst Calendar, Big Mover™ stocks to watch, & model portfolios. Database & tools to help with your biotech stock research & analysis. not investment advice.